Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Asian Pacific journal of cancer prevention : APJCP
- Publicado em
- 1 mai 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Ni Putu Sri Indrani Remitha, Ni Putu Rista Pradnya Dewi, I Komang Wira Ananta Kusuma, I Gede Aswin Parisya Sasmana, I Gede Putu Supadmanaba, Dwijo Anargha Sindhughosa, I Ketut Mariadi
Descritores MeSH
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Hepatocellular
- Phenylurea Compounds
- Quinolines
- Bevacizumab
- Liver Neoplasms
- Humans
- Prognosis
- Survival Rate
Veja também
Estudos relacionados
- A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma
- Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies
- Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
- Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis